Member Info for Shpunken

They must be very confident that the price will hold and substantially increase later to pull it something like that.. that’s not a small amount to gamble with

I was thinking that as well, but odd timing.. still very strange behaviour by them

Very strange as they are increasing their exposure, why not just buy shares, what r they up to

Oh no, how can this be, lol

Still plenty of time prior to the news so if u r a trader this is the time to do it.. only thing that can take the sp below 173 is a delay our last patient rns.. if that goes smoothly, we will be trading within a new range which is being created

Skipp u have missed the point entirely, I am not questioning the vaccine, ofc it works and works well, what I am saying is that atm to be considered vaccinated, 2 doses are enough, but it looks like they will be turning that into 3 and that will create a mess with the covid passes for travelling etc.. who’s to say that if things go south whos to say that they wont make it into 4 jabs etc.. many ppl don’t need more than 2 jabs but governments, like in Israel, will push ppl to do that to take their freedoms bk, and that’s the point I am making.. nothing to do with the efficacy of vaccines, more to do with a looming mess this can cause for all of us

I suggested about a year ago that 2 jabs might turn into 3 for u to be considered vaxed, and this could happen sooner than I thought.. the issue here is that ppl who won’t need them might have their freedoms limited, and that can turn ugly.. governments need to stick to 2 jabs and not create more problems for the rest of us…

And there we have it 192, the top end of our channel. Next week will be very interesting if we finish above that lvl.. impressive buying even when we had a huge flurry of sells around 12ish

Book was filled with sells at 181 and it looked dead certain that the sp will drop from the pressure.. somehow all those sells have been absorbed, are we actually about to see a finish above 192 lol someone is definitely buying, non stop today

Wood, it doesn’t matter that it did, we are still within the old channel, and we need to finish above 192 for us to even have a chance of trying to break into the £2 zone.. we still have at least 2 months until P3 results so expect to see more volatility within the same channel.. unless ofc II start aggressively accumulating, then we could be in for a big surprise

Our wage bill is tiny so in case of success they will deserve all the options they have and more

Daveboy u have to understand that other factors have changed.. before we were expecting our P3 last patient rns by end of September.. now it’s November, and that is still an uncertainty, traders will never leave cash in a stock for too long if they know delays could happen, hence why sp doesn’t hold.. ull see how the sp will react if we get no more delays, I am expecting a new channel and for us to hit a new all time high

Todays news was known already, last patient is more important to free up the sp from its channel.. traders know that delays happen and that’s why the last patient rns will have a bigger effect on the sp.. after that we will have only both P3 results to look forward to

Too early for that, traders are waiting for that last patient rns, it’s the only thing holding bk the sp now.. after that we will be entering new waters

Will be done very quickly now, great update, looking forward to our last patient dosed rns

SP isn’t down, this had 0 effect on the opening sp.. everyone understands it’s a non event

Nothing to do with us though

Japanese drugmaker Shionogi & Co. said the COVID-19 pill it’s developing could be a $2 billion (¥223.7 billion) drug potentially used in combination with a similar offering from Merck & Co., as the pandemic’s focus shifts to the need for easy-to-take medications able to combat mild cases.
Shionogi expects to have late-stage trial data for its pill by December and will move quickly on filing for regulatory approval in Japan. “If the Merck price — about $700 (¥78,300) per treatment — can be used for the U.S., Europe and Japan, I think at least $1-2 billion in sales will be anticipated for the first several years,” Teshirogi said of Shionogi’s pill.

FYI Merck already being questioned and lots of skeptics. Article in bloom says covid could outsmart it

One final assault on 140, potential 143 finish

That pattern was odd, poly are very good at getting their shares on a cheap lol another daylight robbery